Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBT Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBT Margin for 13 consecutive years, with 292.27% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 9131.0% to 292.27% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 149.29% through Dec 2025, up 14616.0% year-over-year, with the annual reading at 120.27% for FY2025, 11714.0% up from the prior year.
  • EBT Margin for Q4 2025 was 292.27% at Theravance Biopharma, up from 14.45% in the prior quarter.
  • The five-year high for EBT Margin was 292.27% in Q4 2025, with the low at 1589.4% in Q1 2022.
  • Average EBT Margin over 5 years is 188.29%, with a median of 100.26% recorded in 2022.
  • The sharpest move saw EBT Margin soared 496978bps in 2021, then plummeted -103212bps in 2022.
  • Over 5 years, EBT Margin stood at 387.84% in 2021, then surged by 75bps to 97.34% in 2022, then skyrocketed by 71bps to 28.56% in 2023, then skyrocketed by 804bps to 200.97% in 2024, then surged by 45bps to 292.27% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 292.27%, 14.45%, and 279.47% for Q4 2025, Q3 2025, and Q2 2025 respectively.